Novogene Co., Ltd. (SHA:688315)

Market Cap	5.71B -3.1%
Revenue (ttm)	2.26B +5.6%
Net Income	162.52M -20.1%
EPS	0.40 -17.8%
Shares Out	405.06M
PE Ratio	35.24
Forward PE	27.36
Dividend	0.05 (0.31%)
Ex-Dividend Date	Jun 10, 2025

Volume	2,928,961
Open	14.40
Previous Close	14.48
Day's Range	13.95 - 14.45
52-Week Range	12.73 - 18.24
Beta	0.73
Analysts	Strong Buy
Price Target	16.62 (+17.96%)
Earnings Date	Aug 14, 2026

About Novogene

Novogene Co., Ltd., together with its subsidiaries, provides genomic services and solutions in Mainland China, Hong Kong, Macau, Taiwan, and internationally. The company offers genomic solutions comprising human, animal, plant, and microbial whole genome sequencing, as well as human and mouse whole exome sequencing, microbial de novo sequencing, animal and plant de novo sequencing, and 12S/18S/ITS amplicon and shotgun metagenomic sequencing; transcriptomics solutions, such as mRNA, long non-coding RNA, small RNA, circular RNA, whole transcripto...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 2,225
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688315

Financial Performance

In 2025, Novogene's revenue was 2.21 billion, an increase of 4.66% compared to the previous year's 2.11 billion. Earnings were 166.95 million, a decrease of -15.16%.